Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 12/20 | 0.70 |
| ▸ | PSEN2 | P49810 | 12/20 | 0.70 |
| ▸ | APH1B | Q8WW43 | 12/20 | 0.70 |
| ▸ | NCSTN | Q92542 | 12/20 | 0.70 |
| ▸ | APH1A | Q96BI3 | 12/20 | 0.70 |
| ▸ | PSENEN | Q9NZ42 | 12/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | CCKBR | P32239 | 5/20 | 0.57 |
| ▸ | CCKAR | P32238 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370070 | 1.00 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3587719 | 0.98 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3588536 | 0.94 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13675154 | 0.92 | KCNH2 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3595087 | 0.92 | KCNH2 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13865657 | 0.92 | KCNH2 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13502683 | 0.90 | KCNH2 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3588681 | 0.90 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3582685 | 0.90 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13502678 | 0.87 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | claimed |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-06 | — | — | US | claimed |
| US-7053081-B2 | Cyclic malonamides as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | claimed |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | OLSON RICHARD E (US) | 2005-01-13 | — | — | US | claimed |
| US-6759404-B2 | INHIBITING GAMMA-SECRETASE ACTIVITY; TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID PRODUCTION, SUCH AS ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | claimed |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | claimed |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMAPNY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMAPNY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMAPNY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | disclosed |
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-06-22 | — | — | US | disclosed |
| US-7053081-B2 | Cyclic malonamides as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | OLSON RICHARD E (US) | 2005-01-13 | — | — | US | disclosed |
| US-6759404-B2 | INHIBITING GAMMA-SECRETASE ACTIVITY; TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID PRODUCTION, SUCH AS ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135762-A1 | Cyclic malonamides as inhibitors of Abeta protein protection | APP, BACE1, APBA1 | PSEN1 6/4885PSEN2 9/4885APH1B 5/4885 |
| US-20020103184-A1 | Cyclic malonamides as inhibitors of a beta protein production | APP, BACE1, APH1A | PSEN1 6/4885PSEN2 8/4885APH1B 4/4885 |
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | PSEN1 6/4885PSEN2 9/4885APH1B 5/4885 |
| US-20100009965-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | APP, BACE1, APBA1 | PSEN1 6/4885PSEN2 9/4885APH1B 5/4885 |
| US-20100041639-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | PSEN1 6/4885PSEN2 8/4885APH1B 4/4885 |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | APP, BACE1, APH1A | PSEN1 6/4885PSEN2 8/4885APH1B 5/4885 |
| US-20050009807-A1 | Cyclic malonamides as inhibitors of A-Beta protein production | APP, APBA1, APH1A | PSEN1 6/4885PSEN2 8/4885APH1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.